YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Editas Medicine EDIT announced that it has received approval to initiate the first-in-human phase I/II Strive clinical study of EDIT-401, its investigational in vivo gene-editing candidate for heterozygous familial hypercholesterolemia (He…
Healthcare stocks were lower late Thursday afternoon, with the NYSE Healthcare Index shedding 0.6% a PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
[Genetic engineeering concept] PhonlamaiPhoto/iStock via Getty Images Editas Medicine (EDIT [https://seekingalpha.com/symbol/EDIT]) traded higher on Thursday after Australian authorities cleared a Phase 1/2 trial for the company’s gene-edi…
Microsoft upgraded, HubSpot initiated: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled…
A month has gone by since the last earnings report for Editas Medicine (EDIT). Shares have added about 6.2% in that time frame, outperforming the S&P 500. But investors have to be wondering, will the recent positive trend continue leading…
[mRNA or messenger RNA. The concept of mRNA vaccine. Innovative methods to treat virus. 3d render] Krot Studio INVESTORS SHOULD KNOW: A major Phase 3 trial win from Moderna (MRNA [https://seekingalpha.com/symbol/MRNA]) and Merck (MRK [http…
Gene editing is emerging as a potentially transformative approach to medicine because it seeks to address disease at its genetic source rather than primarily managing downstream symptoms. Unlike conventional therapies that may require chro…
Quick Read Moderna's 177% stock surge to a ~$70B market cap makes ABUS a prime target, as buying it eliminates $1.3B in LNP patent exposure. NTLA's Phase 3 lonvo-z showed 87% fewer hereditary angioedema attacks, while EDIT offers cardiomet…
[US 100 dollar bill folded into an up arrow on wooden table. Illustration of the concept of inflation, profit, earning and investment] Biotech stocks have reached their highest level since the height of the pandemic after Moderna (MRNA [ht…
Editas Medicine EDIT incurred a loss of 15 cents per share in the second quarter of 2026, narrower than the Zacks Consensus Estimate of a loss of 30 cents. The company had reported a loss of 63 cents per share in the year-ago quarter. Coll…
A month has gone by since the last earnings report for Editas Medicine (EDIT). Shares have lost about 12.4% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, o…
Key Points CRISPR Therapeutics holds a first-mover advantage as a commercial-stage leader with an approved gene-editing therapy on the market. Editas Medicine is strategically pivoting toward in vivo gene editing to target a broader range…
Gene-editing technology has moved from science fiction to clinical reality, forcing investors to choose between commercial leaders and early-stage innovators. Deciding between CRISPR Therapeutics AG(NASDAQ:CRSP) and Editas Medicine(NASDAQ:…
(RTTNews) - Today's Top Gainers list features Q32 Bio, which announced a $55 million private placement financing; Soligenix, which is exploring the suitability of its ThermoVax platform to fight the Bundibugyo strain of Ebola virus; P3 Hea…
(RTTNews) - Editas Medicine Inc. (EDIT), a gene-editing company, on Tuesday released positive preclinical data for EDIT-401, an in vivo gene-editing system, in treating hyperlipidemia. The data was presented at the 94th European Atheroscle…
CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced that it has commenced an underwritten publ…
Custom Market Insights [220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Genome Editing Market size & share revenue was valued at approximately USD 11.2 Billio…
CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, shared new preclinical data supporting the continued advan…
Editas Medicine EDIT incurred a loss of 26 cents per share in the first quarter of 2026, narrower than the Zacks Consensus Estimate of a loss of 30 cents. The company had reported a loss of 43 cents per share in the year-ago quarter. Loss…
Shares of Marathon Petroleum Corporation (MPC) gained 3.2% after the company reported first-quarter 2026 earnings of $1.65 per share, beating the Zacks Consensus Estimate of $0.72 per share. Editas Medicine, Inc.’s (EDIT) shares gained 1.3…
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Editas Medicine, Inc. (EDIT) : Free Stock Analysis Report Regeneron Pharmaceuticals,…
A month has gone by since the last earnings report for Editas Medicine (EDIT). Shares have added about 3.8% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or…
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report McKesson Corporation (MCK) : Free Stock Analysis Report Editas Medicine, Inc. (EDIT)…
When looking only at the past 12 months, Editas Medicine(NASDAQ: EDIT), a small-cap biotech company, seems to be doing well. The drugmaker's shares have soared by 80% over this period. However, zooming out gives a different picture: Editas…
Editas Medicine EDIT reported a loss of 6 cents per share in the fourth quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of 27 cents. The company had incurred a loss of 55 cents per share in the year-ago quarter. The c…
CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that management will participa…
A month has gone by since the last earnings report for Editas Medicine (EDIT). Shares have lost about 8.3% in that time frame, underperforming the S&P 500. But investors have to be wondering, will the recent negative trend continue leading…
Image source: The Motley Fool. DATE Wednesday, August 7, 2024 at 12:03 p.m. ET CALL PARTICIPANTS Chief Executive Officer — Gilmore O’NeillChief Medical Officer — Baisong MeiChief Financial Officer — Erick LuceraChief Scientific Officer — L…
Novo Nordisk NVO reported disappointing top-line data from the two-year primary analysis of two late-stage studies evaluating Rybelsus (oral semaglutide 14 mg) for early-stage symptomatic Alzheimer’s disease (AD). Shares of the company los…
Biogen BIIB announced the signing of a research collaboration agreement with privately held Dayra Therapeutics to discover and develop oral macrocyclic peptides for priority targets in immunological conditions. Rationale Behind the BIIB/Da…
AstraZeneca AZN announced that the FDA has approved its oral, selective MEK inhibitor, Koselugo (selumetinib), for expanded use. The drug is now indicated to treat symptomatic, inoperable plexiform neurofibromas (PN) in adult patients with…
Shares of Cogent Biosciences COGT have skyrocketed 120.3% in a month. The stock price rally was primarily driven by positive data readout from a late-stage study of its investigational combo therapy, bezuclastinib plus sunitinib, in second…
An updated edition of the Sept. 18, 2025, article. Genomics is a comprehensive study of genomes (an organism’s complete set of deoxyribonucleic acid or DNA). Given the recent promising breakthroughs in this field, the space is drawing inte…
Editas Medicine EDIT reported a loss of 28 cents per share in the third quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of 38 cents. The company had incurred a loss of 75 cents per share in the year-ago quarter. Colla…
Janux Therapeutics, Inc. (JANX) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.6. This compares to a loss of $0.51 per share a year ago. These figures are adjusted for non-recurring it…
Gilead Sciences (GILD) came out with quarterly earnings of $2.47 per share, beating the Zacks Consensus Estimate of $2.15 per share. This compares to earnings of $2.02 per share a year ago. These figures are adjusted for non-recurring item…